Top Biotech Companies in Singapore (93)
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health...
AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
Novotech is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, "Novotech" and "PPC". Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture...
Thermo Fisher Scientific's Top Stability & Growth Strengths
Strong Market Position & Advantage: Thermo Fisher’s scale and breadth—largest revenue in 2025 (~$44.6B), leadership across a moderately consolidated tools market, and a top‑tier market value—support clear category leadership. Third‑party benchmarking and peer comparisons (e.g., relative to Danaher) reinforce its platform advantage.
Diversified Revenue Streams: A broad, integrated portfolio spanning instruments, consumables, diagnostics, distribution, and biopharma services (PPD, Patheon) drives multiple revenue engines and customer stickiness. Recurring consumables/services and distribution contribute steady mix that helps smooth cycles.
Innovation-Driven Growth: Recent product launches (e.g., Glacios 3 Cryo‑TEM, TSQ Certis) and the NVIDIA collaboration to accelerate AI‑enabled and increasingly autonomous lab systems indicate continued innovation momentum. These initiatives position the platform to capture next‑gen workflow demand.
Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery
For over 35 years, IDT has been enabling genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, with the most advanced synthesis, modification, purification, and quality control capabilities available. Through our founder's dedication to innovation, the highest standards of quality, and deep genomics expertise, IDT has evolved from a leading oligo manufacturer to a genomics solutions provider supporting areas such...
Princeton Biopartners is a best-in-class provider of integrated consulting solutions to the life sciences sector. Our mission is to improve the evidence base, accessibility, and impact of biomedical innovations through strategic advisory, software, and our venture fund. We pride ourselves on establishing long-term client relationships and are dedicated to addressing pain points via integrated and transformative projects. Setting new standards...
Novotech is a global full‑service clinical research organization (CRO) and scientific advisory partner that provides clinical trial execution, regulatory, laboratory and consulting services to biotech and small- to mid‑sized pharmaceutical companies. Operating across the Asia‑Pacific region and beyond with multiple offices and strategic site partnerships, Novotech helps sponsors accelerate development and access diverse patient populations for global drug development.
Entobel is converting low value organic substrate into high quality products thanks to insects. Our main current products are sustainable animal feed (proteins and oils) and organic fertilizer. Since 2013, Entobel is running a commercial scale production site in Vietnam and exporting products worldwide. Entobel complies with highest standards in the industry (ISO 22000), only use tracable feedstocks and is...
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
AstraZeneca's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising strongly, with 2024 up to $54.1B and continued momentum into 2025 alongside management’s stated 2030 ambition. The trend is broad‑based across oncology and biopharma, with repeated beats and reaffirmed guidance supporting durability.
Strong Market Position & Advantage: Market position is top‑tier globally by value and leadership is pronounced in oncology, where the company ranks among the top three by revenue with multiple anchor assets. Scale and execution in the U.S. and other key markets underline competitive advantage.
Innovation-Driven Growth: Pipeline and approvals are driving expansion, with multiple 2025 U.S. FDA wins for ADCs, an expanded first‑line label for Enhertu, and a deep ASCO 2025 presence across ADC, I/O, targeted agents, and SERD.
Syngenta Group is a leading global agricultural technology (AgTech) company headquartered in Basel, Switzerland. With over 50,000 employees across more than 90 countries, it provides farmers with innovative technology and expertise to increase productivity and ensure the growth of healthy, affordable, and sustainable food. The company is a world market leader in sustainable agriculture, offering a diverse portfolio of seeds...
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
With offices in Europe, North America and APAC, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools &...
We are a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Our technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Our programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted...
Hummingbird Bioscience is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency...
Biofourmis is a fast-growing digital health company filled with committed, passionate people who care about augmenting personalized care and empowering people with complex chronic conditions to live better and healthier lives. We are pioneering an entirely new category of medicine, by developing clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and...
Lion TCR is a clinical-stage biotechnology company dedicated to the continued development and commercialization of our TCR-T therapy.
We are a molecular life science company dedicated to advancing human health through innovation. By designing and building breakthrough molecular platforms that are both accessible and best-in-class, One BioMed is providing biomedical researchers and clinicians with unprecedented access to cutting-edge tools.
